ADMA Biologics (ADMA) Set to Announce Quarterly Earnings on Thursday

ADMA Biologics (NASDAQ:ADMA) is set to announce its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of $0.13 per share for the quarter. ADMA Biologics has set its FY 2024 guidance at EPS and its FY 2025 guidance at EPS.Persons that are interested in registering for the company’s earnings conference call can do so using this link.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The firm had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. During the same quarter in the previous year, the firm posted ($0.02) earnings per share. The business’s revenue was up 78.4% on a year-over-year basis. On average, analysts expect ADMA Biologics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ADMA Biologics Stock Down 1.9 %

Shares of ADMA stock traded down $0.36 during trading hours on Tuesday, hitting $18.75. 806,652 shares of the company were exchanged, compared to its average volume of 3,625,680. ADMA Biologics has a 52 week low of $3.54 and a 52 week high of $21.13. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74. The business has a 50 day moving average of $17.88 and a two-hundred day moving average of $13.56. The company has a market capitalization of $4.37 billion, a PE ratio of 136.50 and a beta of 0.64.

Insider Buying and Selling

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the transaction, the director now directly owns 153,941 shares in the company, valued at $2,843,290.27. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the sale, the director now owns 153,941 shares in the company, valued at $2,843,290.27. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the transaction, the director now directly owns 241,441 shares of the company’s stock, valued at approximately $4,408,712.66. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 466,900 shares of company stock worth $8,224,121. Corporate insiders own 3.70% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on ADMA. Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of ADMA Biologics in a research note on Monday, October 14th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ADMA Biologics presently has a consensus rating of “Buy” and a consensus price target of $15.50.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.